|

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

RECRUITINGSponsored by HK inno.N Corporation
Actively Recruiting
SponsorHK inno.N Corporation
Started2023-09-25
Est. completion2026-12
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06389552

Summary

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age over 19 at the time of obtaining the informed consent form
* Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
* ECOG 0 or 1
* Scheduled to RO or R1 resection
* Organ function capable of chemotherapy

Exclusion Criteria:

* FOLFIRINOX contraindications among the drug approval requirements
* Palliative Therapy
* Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX

Conditions2

Adjuvant ChemotherapyCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.